Breast Cancer Clinical Trials

None

None

Transcutaneous Breast Cancer Diagnosis by Canine Odorology

Patient with an indication of interventional percutaneous procedure for characterization of a breast lesion, palpable or not, classified as category 4 or 5, according to the Breast Imaging (BI) Report and Data System of the American College of Radiology (RADS) classification detected at mammography and/or breast ultrasound examination.

Radiofrequency Ablation (RFA) in Breast Tumors

To validate the efficacy and safety of the cool-tip ablation method for breast tumors smaller than 2 cm.

SBRT for Breast Cancer Oligometastases

This is a prospective data collection of treatment outcome for newly diagnosed oligometastatic breast cancers with 1-3 bone metastases. Eligible patients will be identified from the weekly Breast MDC. Patients will receive the recommended systemic and local treatment (including metastases directed SBRT) according to our clinical practice guidelines.Patients will be …

BREast Cancer And Sexuality Treatment

Groups will consist of approximately 8 breast cancer survivors and will be led by 2 trained therapists. Participants will complete four assessments (involving a clinician administered interview and standardized questions): pre-treatment, post- treatment, and 6 month follow up.

Genetic Characteristics of Metastatic Breast Cancer Patients

Genomic analysis for metastatic breast cancer(MBC) patients Participant (Inclusion criteria) Patients who diagnosed metastatic/stage IV breast cancer Patients who were not received treatment for metastatic breast cancer on palliative setting Process (1) Tissue/ Blood sample At diagnosis, MBC tissue / blood sample (20cc) will be obtained.

Multi-4SCAR-T Therapy Targeting Breast Cancer

The purpose of this study is to assess the feasibility, safety and efficacy of multiple 4th generation CAR-T cells targeting Her2, GD2, and CD44v6 surface antigen in breast cancer. Another goal of the study is to learn more about the activities of the multi-CAR T cells and their persistency in …

CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer

Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also receive Stereotactic Body Radiation Therapy(SBRT) to each metastatic lesion.

Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer

This study is to evaluate the efficacy of tucidinostat combined with exemestane as neoadjuvant strategy in estrogen receptor-positive early breast cancer patients and explore the genetic model which can predict neoadjuvant endocrine therapeutic results.